Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announce the recent approval of Xadago®/safinamide in Australia by the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health for the treatment of adult patients with fluctuating idiopathic Parkinson’s disease (PD) as add-on therapy to a regimen that includes levodopa (L-Dopa).
For more information: https://www.newron.com/en